Diabetes drug teams up with immunotherapy in fight against tough cancer
NCT ID NCT04414540
Summary
This study is testing if adding a common diabetes medication (metformin) to an established cancer immunotherapy (pembrolizumab) can better control advanced head and neck cancer that has spread or returned. It involves about 20 patients who have run out of standard curative options. Researchers want to see if this drug combination is safe and can shrink tumors or slow the cancer's growth.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Cincinnati Medical Center
Cincinnati, Ohio, 45219, United States
Conditions
Explore the condition pages connected to this study.